3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
9
Gastrointestinal
5
Thoracic
4
Breast
4
Genitourinary
3
Dermatologic
3
Head & Neck
2
CNS
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Herpes Zoster
1
Hematologic Neoplasms
1
Interventions
Cytarabine
465
Cyclophosphamide
459
fludarabine phosphate
277
Rituximab
249
Methotrexate
245
Etoposide
203
fludarabine
200
Filgrastim
199
Peripheral Blood Stem Cell Transplantation
180
Busulfan
169
Vincristine
163
Dexamethasone
153
Daunorubicin
151
Azacitidine
145
Mycophenolic Acid
142
Whole-Body Irradiation
133
Tacrolimus
127
Imatinib Mesylate
127
Cyclosporine
123
Granulocyte Colony-Stimulating Factor
118
Radiotherapy
113
Melphalan
110
Idarubicin
103
Doxorubicin
101
Mitoxantrone
97
Decitabine
97
Antilymphocyte Serum
97
Lenalidomide
96
Mercaptopurine
93
Prednisone
91
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Vaccines
×
Other hematologic neoplasm
×
Clear all
NCT01254630
2019-09-30
V212-011
Merck Sharp & Dohme LLC
Phase 3
Completed
5,305 enrolled
20 charts